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 In conclusion, the conventional model of cell inactivation based on in 
vitro survival curves which can be described by the L-Q formalism is 
being complemented by complex mechanisms involving the cellular 
radiation response, interaction with other target cells, and the 
influence of the microenvironment and systemic factors. 
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Background: In 2010, we reported data on local control and early 
toxicity for theTARGIT-A trial of intraoperative radiotherapy after 
lumpectomy for early breastcancer (n = 2232, Vaidya et al, Lancet). 
Randomisation continued until a totalnumber of 3451 patients were 
included in June 2012. We present the updatedresults on local control 
and the first analysis of survival of the wholecohort. 
Methods: TARGIT-A was a randomised trial in patients >=45 years with 
invasive ductal carcinoma undergoing breast conserving surgery 
comparing standard fractionated whole breast EBRT (3-6 weeks) with 
single dose TARGIT (20 Gy)either given at the time of the primary 
operation (prepathology stratum) or ina delayed second procedure 
(post pathology stratum). The experimental arm mandated additional 
EBRT excluding a boost, if adverse features were detected on final 
pathology making this a “risk-adapted policy”. 3451, 2020 and 1222 
patients have a median follow-up of 2.5, 4 and 5 years, respectively. 
The primary outcome was ipsilateral within breast recurrence (IBR) 
with an absolute non-inferiority margin of 2.5% at 5 years and 
secondary outcome was survival. 
Results: 1721 patients were randomly allocated to receive TARGIT and 
1730 to EBRT. Primary events have increased from 13 to 34 since2010. 
For the primary outcome of ipsilateral breast recurrence, the absolute 
difference at 5-years was 2.0% (3.3% vs. 1.3%), which was higher with 
TARGIT; in prepathology the absolute difference in 5-year IBR was 1%; 
in post pathology it was 3.7%. For the secondary outcome, there was a 
non-significant trend for improved overall survival with TARGIT (HR = 
0.70) due to fewer non-breast cancer deaths (17 vs. 35, HR 0.47). 
Conclusion: Patients in the TARGIT-A trial have excellent 5 year 
outcomes (local control > 96%, overall survival >= 94%) in both arms of 
the trial. 
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Background: To assess the role of an intraoperative electron boost 
(IOERT) in combination with hypofractionated whole breast irradiation 
(WBI) in terms of in-breast tumor control and cosmeticoutcome. 
Methods: Starting in Jan 2011, a prospective multi-center single arm 
trial is conducted by the ISIORT. Patients receive an IOERT boost of 10 
Gy ( Dmax 11.1 Gy) followed by a WBI of 40.5 Gy in 15 fractions (2.7 
Gy single dose). 5-year in-breast-recurrence rates will be analyzed in 
3 different age groups (35–40y, 41-50y, >50y) and tested against the 
respective best published results from randomized prospective trials 
by the use of a sequential probability ratio test (SPRT). Acute 
reactions are assessed by CTC-scoring, late reactions according to 
LENT-SOMA criteria. Cosmesis is evaluated by a 5-point-Scoring System 
(van Limbergen, double evaluation) starting prior to WBI on the basis 
of repeated photodocumentation in standardized positions. 
Results: As of Jan2013, within six active institutions 327 patients have 
been recruited, 204 of them already in follow-up. Patient and tumor 
characteristics are summarized in Table 1.  
  
  
For IOERT, the median energy chosen was 6 MeV(range 4-12) with 
median tube diameters of 6 cm (3-8) and mean prescription depths of 
20 mm (13.8 SD), resulting in mean D90 volumes of 37 ml.  
Perioperatively, no major complications were observed. Four weeks 
after the end of WBI, 60 patients (29.8%) showed no reactions (CTC 0), 
130 patients (66.2%) presented with faint (CTC 1) and eight (4%) with 
moderate to brisk erythema (CTC 2),respectively. Four to five months 
after the end of treatment, late reactions according to LENT-SOMA 
criteria were assessed in 159 patients, all of them scored as grade 0. 
At one year post WBI, 74 patients still presented as grade 0, one 
patient as grade 1. 
Cosmesis was assessed postoperatively in 217 patients, 159 were 
evaluated 4-5 months and 75 one year after the end of WBI, 
respectively. Baseline appearance prior toWBI was scored as excellent 
(E0) in 31.8/17.5% (patients/doctors), good (E1) in 52/50.4%, 
moderate (E2) in 14.3/27.6%, bad (E3) in 1.4/4.5% and complication 
(E4) in 0.5/0%.  At 4 months post RT, there was a trend towards 
better rating:  E0: 34.6/21.3%; E1: 51.6/46.9%; E2: 12.6/27.3%,E 3: 
1.2/4.5%.  Results at 12 months follow-up were similar. 
At a median follow-up period of 12 months (3-16), no recurrence was 
noted. 
Conclusion: Tolerance of a combined IOERT / hypofractionated WBI 
regimen is excellent, acute reactions moderate and late reactions 
insignificant in short-term assessment. With regard to postoperative 
appearance, early cosmetic results are not impaired. Both tumor 
control and cosmetic outcome have to be evaluated on long-term 
follow-up. 
 
SP-0384   
IORT Boost: randomised prospective trial 
A. Ciabattoni1 
1Ospedale San Filippo Neri, Unità Operativa Complessa di 
Radioterapia, Roma, Italy  
S150  2nd ESTRO Forum 2013	
 
Purpose: Many published reports have demonstrated that early stage 
breast cancer patients need a radiotherapy boost on tumor bed after 
breast conserving surgery (BCS) and whole breast irradiation. Linac-
based IORT boost with electrons was implemented to prevent the 
contamination with subclinical tumor cells in the vicinity of tumor 
site, followed by external beam radiotherapy. A IORT boost may allow 
to reduce the incidence of local recurrence, obtaining good esthetical 
results compared to external beam boost, due to skin sparing. In 
addition to whole breast irradiation (WBI), it has yielded excellent 
long-term results. The aim of this study is to present the long term 
follow up results on local control, esthetic evaluation and toxicity of a 
randomized prospective study on early stage breast cancer patients 
treated with IORT boost of 10 Gy versus the same external beam dose.  
Material and Methods: A randomized prospective study on IORT versus 
external beam boost in early breast cancer patients was carried on in 
our Institution. Primary endpoints of the study were the evaluation of 
local recurrence(LR), toxicity and cosmetic result. 
From April 1999 to April 2004, 244 patients were enrolled: 126 in IORT 
arm (131 treatments for 5 bilateral) and 118 in no IORT arm. The 
average age was 49.2 and 50 7 respectively. 
Toxicity valuation was assessed using EORTC/RTOG scale. The 
cosmetic result was detected on five parameters: hyper-pigmentation, 
telangiectasias, hypertrophic scar, profile asymmetry and difference 
in consistency. 
Results: The median follow-up was 130,6 months (range 96-156 
months). Ten patients were lost at the follow up. Sixty women (24,6%) 
were younger than 45 years, 33 in IORT and 27 in no IORT arm. Two 
and five true local recurrences were observed in IORT and no IORT 
arm respectively. Both of the IORT arm recurrences were observed at 
more than 100 months follow up: one of them (in field) was a 62 years 
old woman, with apT1bN0M0 G2 infiltrating ductal carcinoma (IDC), 
after 100 months and the other (marginal) was a 56 years old 
pT1cN0M0 G3 IDC, after 112 months follow up. A third patient 
presented an ipsilateral out of field recurrence: she was a 72 years old 
with a pT1cN0M0 G3 IDC, after 120 months follow up. The mean time 
to recurrence in no IORT group was earlier (55,2 months). One patient 
was a 46 years old, pre-menopausal, with a pT2N2M0 G3 IDC, after 50 
months; one was a 51, pre-menopausal, pT1cN0M0 G3 medullary 
carcinoma, after 40 months; one patient was 69 pT1cN0M0 G2 IDC 
after 45 months; one was 67, pT1cN0M0 G3 IDC, after 56 months; the 
last was a 71 years old woman, pT1cN0M0 G2 infiltrating lobular 
carcinoma, after 90 months. 
No local failures were observed in the group of IORT pre-menopausal 
women.  
As acute toxicity 12 patients developed post-surgical seromas and 7 
wound healing problems occurred (7,8%). No late complications 
associated with IORT were observed, but three cases of liponecrosis in 
the treatment area. In 5 patients, a secondary mastectomy was 
performed for tumour multi centricity or excessive intraductal 
component. Cosmetic result was very good (objective valuation 92,8% 
good or excellent, subjective valuation 90,2%) and comparable to 
patients treated with external boost (87,4% good or excellent). The 
DFS was 89,1% and 86,4% in IORT and no IORT arm, 22 patients 
developed distant metastasis and 19 died (fourteen of them for 
disease).  
Conclusion: Our data suggest that IORT as anticipated boost after 
breast-conserving surgery can be performed without significant 
morbidity and it’s a reliable alternative to conventional postoperative 
external beam boost,  particularly in younger women, for whom 
published studies indicate higher risk of local recurrence. The 
incidence of recurrence with the IORT boost, for any age, including 
young women, is quite low. Further research is required to clarify 
several issues such as identification of the most appropriate subgroups 




   
 DEBATE: DOES THIS HOUSE BELIEVE THAT WE CAN 
AVOID SURGERY IN RESPONDER RECTAL CANCER 
PATIENTS?  
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Chemoradiation (CRT) has been shown to lead to downsizing in an 
important part of rectal cancers. In 15-20% of cases even a 
pathological complete response (pCR) occurs. In order to tailor 
treatment at an earlier stage, predictive models are being developed. 
Accurate prediction could enable more individualised surgical 
approaches, including less extensive resection or even a wait-and-see 
policy. Furthermore, also CRT could be tailored based on tumor 
response prediction.  
In our research groups several response prediction models for rectal 
cancer have been developed, mainly based on longitudinal PET-
imaging, on MR imaging and on multifactorial nomograms including 
clinical parameters. Furthermore, an innovative method consists of 
adding CT- based features for pre-treatment response prediction in 
rectal cancer, the so-called “radiomics” approach. More recently, also 
biomarkers have been added to the prediction models, since they can 
add important biological information to the prediction model and can 
be collected very easily in clinical practice. We conclude that imaging 
based models and the nomogram developed based on clinical, 
biological and sequential imaging data can accurately predict tumor 
response, and can be used as a decision support tool for individualized 
treatment approaches including surgery avoidance after prospective 
validation. Inclusion of patients developing a clinical complete 
remission after chemoradiation in a wait and see protocol helps us 
further to identify the group of patients in whom surgery can be safely 
omitted. 
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